Nuclear Medicine and Molecular Imaging

Andrew Quon

Publication Details

  • 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma.

    Iagaru A, Quon A, Johnson D, Gambhir SS, McDougall IR. Mol Imaging Biol. 2007 Jan-Feb; 9 (1): 50-7

    2-Deoxy-2-[F-18]fluoro-D-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) is widely available as a powerful imaging modality, combining the ability to detect active metabolic processes and their morphologic features in a single exam. The role of FDG-PET is proven in a variety of cancers, including melanoma, but the estimates of sensitivity and specificity are based in the majority of the published studies on dedicated PET, not PET/CT. Therefore, we were prompted to review our experience with FDG-PET/CT in the management of melanoma.

    PubMedID: 17051322

Stanford Medicine Resources:

Footer Links: